Last reviewed · How we verify
NDI-219216
At a glance
| Generic name | NDI-219216 |
|---|---|
| Sponsor | Nimbus Wadjet, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NDI-219216 CI brief — competitive landscape report
- NDI-219216 updates RSS · CI watch RSS
- Nimbus Wadjet, Inc. portfolio CI